JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$5.47B |
| 2 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$3.17B |
| 3 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$2.05B |
| 4 |
Amazon
AMZN
|
+$1.96B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.6B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$1.72B |
| 2 |
Vanguard Intermediate-Term Treasury ETF
VGIT
|
+$1.31B |
| 3 |
UnitedHealth
UNH
|
+$1.26B |
| 4 |
Automatic Data Processing
ADP
|
+$1.17B |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$1.08B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 27.28% |
| 2 | Technology | 17.17% |
| 3 | Healthcare | 10.79% |
| 4 | Financials | 9.36% |
| 5 | Consumer Discretionary | 8.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
4201
First Trust Large Cap Growth AlphaDEX Fund
FTC
$1.37B
| $578K | ﹤0.01% |
6,206
+5,267
| +561% | +$490K |
2022 Q4
1 quarter
|
|
4202
ADMA Biologics
ADMA
$2.28B
| $577K | ﹤0.01% |
174,224
-110,684
| -39% | -$383K |
2021 Q4
5 quarters
|
|
4203
iShares Broad USD Investment Grade Corporate Bond ETF
USIG
$17.5B
| $577K | ﹤0.01% |
11,380
-19,937
| -64% | -$1M |
2018 Q4
17 quarters
|
|
|
OLO
4204
DELISTED
Olo Inc
OLO
| $576K | ﹤0.01% |
70,647
+16,586
| +31% | +$128K |
2021 Q1
8 quarters
|
|
4205
CALL
Sunrun
RUN
$1.87B
| $576K | ﹤0.01% |
28,600
-66,000
| -70% | -$1.54M |
2021 Q2
7 quarters
|
|
|
SHCR
4206
DELISTED
Sharecare, Inc. Class A Common Stock
SHCR
| $575K | ﹤0.01% |
405,216
+89,047
| +28% | +$202K |
2021 Q3
6 quarters
|
|
|
TDCX
4207
DELISTED
TDCX Inc. American Depositary Shares, each representing one Class A ordinary share
TDCX
| $575K | ﹤0.01% |
64,595
-117,134
| -64% | -$1.41M |
2021 Q4
5 quarters
|
|
|
AKRO
4208
CALL
DELISTED
Akero Therapeutics
AKRO
| $574K | ﹤0.01% |
15,000
| – | – |
2022 Q4
1 quarter
|
|
4209
Codexis
CDXS
$149M
| $574K | ﹤0.01% |
138,758
+42,663
| +44% | +$224K |
2017 Q3
22 quarters
|
|
4210
Vanguard ESG International Stock ETF
VSGX
$6.73B
| $573K | ﹤0.01% |
10,939
+3,863
| +55% | +$201K |
2022 Q4
1 quarter
|
|
4211
America's Car Mart
CRMT
$8.92M
| $572K | ﹤0.01% |
7,228
+1,495
| +26% | +$122K |
2017 Q4
21 quarters
|
|
4212
VanEck High Yield Muni ETF
HYD
$3.91B
| $572K | ﹤0.01% |
11,052
-47,382
| -81% | -$2.45M |
2022 Q1
4 quarters
|
|
4213
CALL
Ralph Lauren
RL
$22B
| $572K | ﹤0.01% |
4,900
+2,200
| +81% | +$259K |
2022 Q4
1 quarter
|
|
4214
State Street Nuveen Municipal Bond ETF
MBND
$25.8M
| $571K | ﹤0.01% |
21,051
-53,644
| -72% | -$1.45M |
2021 Q1
8 quarters
|
|
4215
Microvision
MVIS
$48.3M
| $570K | ﹤0.01% |
14,220
-5,938
| -29% | -$225K |
2016 Q4
25 quarters
|
|
|
CCC
4216
CCC Intelligent Solutions
CCC
$3.92B
| $569K | ﹤0.01% |
63,453
+8,922
| +16% | +$79.4K |
2022 Q2
3 quarters
|
|
4217
Invesco DB US Dollar Index Bullish Fund
UUP
$439M
| $568K | ﹤0.01% |
20,384
+6,217
| +44% | +$174K |
2014 Q4
33 quarters
|
|
|
NWLI
4218
DELISTED
National Western Life Group, Inc. Class A
NWLI
| $566K | ﹤0.01% |
2,334
+673
| +41% | +$175K |
2016 Q4
25 quarters
|
|
4219
Pliant Therapeutics
PLRX
$63.8M
| $565K | ﹤0.01% |
21,227
+6,268
| +42% | +$178K |
2020 Q3
10 quarters
|
|
4220
Passage Bio
PASG
$13.1M
| $564K | ﹤0.01% |
29,450
| – | – |
2020 Q2
11 quarters
|
|
|
EXAS
4221
CALL
DELISTED
Exact Sciences
EXAS
| $563K | ﹤0.01% |
8,300
-18,200
| -69% | -$1.17M |
2022 Q4
1 quarter
|
|
|
OLPX
4222
DELISTED
Olaplex Holdings
OLPX
| $563K | ﹤0.01% |
131,852
+17,245
| +15% | +$91.9K |
2021 Q3
6 quarters
|
|
4223
Direxion Daily Regional Banks Bull 3X ETF
DPST
$322M
| $561K | ﹤0.01% |
+7,280
| New | +$1.49M |
2023 Q1
0 quarters
|
|
4224
WisdomTree International SmallCap Dividend Fund
DLS
$1.04B
| $560K | ﹤0.01% |
9,187
+5,413
| +143% | +$332K |
2022 Q4
1 quarter
|
|
4225
iShares New York Muni Bond ETF
NYF
$1.53B
| $558K | ﹤0.01% |
10,430
+8,225
| +373% | +$436K |
2015 Q4
29 quarters
|
|
Similar funds
JP Morgan Chase's Q1 2023 Portfolio in Review
As of Q1 2023, JP Morgan Chase held 7,579 positions worth $821B, up 8.2% from $759B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
JP Morgan Chase's Q1 2023 filing shows 751 new, 3,314 increased, 2,056 reduced and 652 closed positions. Its largest new stake was Near Intelligence, Inc. Common Stock: 5,852,099 shares worth $14.7M. The largest sale was Eli Lilly, an estimated $1.72B.
By sector, the portfolio is most concentrated in Miscellaneous at 27% of assets, up from 27% a quarter earlier, followed by Technology and Healthcare.
- JP Morgan Chase's largest Q1 2023 buy was Near Intelligence, Inc. Common Stock: 5,852,099 shares worth $14.7M.
- JP Morgan Chase added most to JPMorgan BetaBuilders Europe ETF in Q1 2023, an estimated $5.47B increase.
- JP Morgan Chase's biggest Q1 2023 reduction was Eli Lilly, cutting an estimated $1.72B.
- JP Morgan Chase fully exited IAA, Inc. Common Stock in Q1 2023, selling an estimated $155M.
- JP Morgan Chase's ten largest holdings make up 17% of its $821B portfolio in Q1 2023.
- JP Morgan Chase opened 751 new positions and closed 652 in Q1 2023.
- JP Morgan Chase's portfolio value rose 8.2% quarter-over-quarter to $821B.
Based on JP Morgan Chase's 13F filing for Q1 2023, filed 11 May 2023.